Abstract:Background Hospital-onset (HO) carbapenem-resistant Enterobacterales (CRE) infections are increasing; recently, the Centers for Disease Control and Prevention (CDC) reported a 35% increase during the COVID-19 pandemic. We evaluated the impact of HO CRE blood stream infections (BSI) on outcomes compared to community-onset (CO) CRE BSI. Methods Patients prospectively enrolled in CRACKLE-2 from 56 hospitals in 10 countries between April 30, 2016 to November 30, 2019 with a qualifying CRE bloodstream culture were eligible. Infections were defined per CDC guidelines as CO when the culture was obtained immediately prior to admission or through the first three days of hospitalization, and HO when the culture was obtained on or after the fourth day of admission. Categorical variables were tested using a chi-square test; continuous variable distributions were compared using Wilcoxon rank sum and Kruskal Wallis tests, as appropriate. The primary outcome was desirability of outcome ranking (DOOR) 30 days after index culture. Difference in 30-day mortality was calculated with 95% confidence intervals (CI). Results Among 891 patients with CRE BSI (Table 1), 65% of BSIs were hospital-onset (582/891). Compared to those with CO CRE, patients with HO CRE were younger (median 60 [Q1 42, Q3 70] years vs 65 [52, 74]; p< 0.001), had lower Charlson comorbidity score (median 2 [1, 4] versus 3 [1, 5]; p=0.002), and more often had Pitt bacteremia sore ≥4, indicative of critical illness, (47% versus 32%; p=< 0.001). ICU admission prior to first culture was associated with HO BSI (68% versus 42%, p< 0.001). Distribution of DOOR outcome at 30 days is shown in Figure 1. The probability of a better DOOR outcome in a randomly selected patient with CO BSI compared to a patient with HO BSI is 60.6% (95% CI: 56.8-64.3%). Mortality at 30-days was 11.6% higher in HO BSI than CO BSI (95% CI: 5.7, 17.6%, p=0.0003). A Kaplan-Meier curve of all-cause 30-day mortality is in Figure 2Figure 1:Distribution of Desirability of Outcome Ranking (DOOR) Categories by Infection Onset Desirability of outcome ranking at 30-days. Events evaluated included 1) deleterious effects, including absence of clinical response, prolonged hospitalization (>30 days following first positive culture), or readmission within 30 days; 2) any adverse events including renal failure or C. difficile infection; and 3) mortality at 30 days. Two subjects (1 in hospital onset group and 1 in community onset group) missing 30-day DOOR due to missing disposition information are not included in the figure.Figure 2:30-day Survival Plot by Infection Onset Two subjects (1 in hospital onset group and 1 in community onset group) are excluded from the figure due to missing mortality outcome information. One subject in the hospital onset group died on day 30 and is still considered at risk in the figure. Conclusion HO CRE BSIs are associated with worse outcomes than CO CRE BSIs; this unique population warrants special attention. As CRE often contain mobile genetic elements that facilitate horizontal transfer, close monitoring of HO CRE rates and optimizing hospital infection prevention methods are critical to prevent added morbidity and mortality. Disclosures Yohei Doi, MD, PHD, bioMerieux: Advisor/Consultant|FujiFilm: Advisor/Consultant|Gilead: Advisor/Consultant|Gilead: Honoraria|GSK: Advisor/Consultant|Meiji Seika Pharma: Advisor/Consultant|Moderna: Advisor/Consultant|Moderna: Honoraria|MSD: Advisor/Consultant|MSD: Honoraria|Shionogi: Advisor/Consultant|Shionogi: Grant/Research Support|Shionogi: Honoraria Michael J. Satlin, MD, AbbVie: IDMC member|Biomerieux: Grant/Research Support|Merck: Grant/Research Support|SNIPRBiome: Grant/Research Support Vance G. Fowler, MD, MHS, Amphliphi Biosciences, Integrated Biotherapeutics; C3J, Armata, Valanbio; Akagera, Aridis, Roche, Astra Zeneca: Advisor/Consultant|Genentech, Regeneron, Deep Blue, Basilea, Janssen;: Grant/Research Support|Infectious Diseases Society of America: Honoraria|MedImmune, Allergan, Pfizer, Advanced Liquid Logics, Theravance, Novartis, Merck; Medical Biosurfaces; Locus; Affinergy; Contrafect; Karius;: Grant/Research Support|Novartis, Debiopharm, Genentech, Achaogen, Affinium, Medicines Co., MedImmune, Bayer, Basilea, Affinergy, Janssen, Contrafect, Regeneron, Destiny,: Advisor/Consultant|Sepsis diagnostic: Patent pending|UpToDate: Royalties|Valanbio and ArcBio: Stock Options David van Duin, MD, PhD, Entasis: Advisor/Consultant|Merck: Advisor/Consultant|Merck: Grant/Research Support|Pfizer: Advisor/Consultant|Pfizer: Honoraria|Qpex: Advisor/Consultant|Roche: Advisor/Consultant|Shionogi: Advisor/Consultant|Shionogi: Grant/Research Support|Union: Advisor/Consultant|Utility: Advisor/Consultant

Exploration of a Potential DOOR Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Using Six Registrational Trials for Antibacterial Drugs

Improving Traditional Registrational Trial End Points: Development and Application of a Desirability of Outcome Ranking End Point for Complicated Urinary Tract Infection Clinical Trials

Evaluating the Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR) for Clinical Trials of Antibiotics in Pediatric Pneumonia

Desirability of Outcome Ranking for the Management of Antimicrobial Therapy (DOOR MAT) Reveals Improvements in the Treatment of Bloodstream Infections Caused by Escherichia coli and Klebsiella pneumoniae in Patients from the Veterans Health Administration

Desirability of outcome ranking (DOOR) for comparing diagnostic tools and early therapeutic choices in patients with suspected candidemia

Application of desirability of outcome ranking to the milking in non-vigorous infants trial

Association of an In-Hospital Desirability of Outcomes Ranking Scale With Postdischarge Health-Related Quality of Life: A Secondary Analysis of the Life After Pediatric Sepsis Evaluation

The adaptation of the desirability of outcome ranking for interventional clinical trials in epilepsy: A novel consumer‐led outcome measure

Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial

Recombinant Human Activated Protein C for the Treatment of Severe Sepsis and Septic Shock: a Study Protocol for Incorporating Observational Evidence Using a Bayesian Approach.

Combination of anti-staphylococcal β lactam with standard therapy compared to standard therapy alone for the treatment of MRSA bacteraemia: a post hoc analysis of the CAMERA2 trial using a desirability of outcome ranking (DOOR) approach

Leveraging real-world Data from administrative claims and medical records to inform safety and effectiveness of piperacillin-tazobactam in the Management of Pediatric Hospital Acquired Pneumonia

Economic evaluation alongside the Probiotics to Prevent Severe Pneumonia and Endotracheal Colonization Trial (E-PROSPECT): study protocol

Increased mortality in hospital- compared to community-onset carbapenem-resistant enterobacterales infections

Evaluating probiotics for the prevention of ventilator-associated pneumonia: a randomised placebo-controlled multicentre trial protocol and statistical analysis plan for PROSPECT

Rationale and study design for an Individualized PeriopeRative Open lung VEntilatory approach in Emergency Abdominal Laparotomy/scopy: study protocol for a prospective international randomized controlled trial

Improving Antibiotic Use for Ventilator-Associated Pneumonia Through Diagnostic Stewardship: A Proof-of-Concept Mixed Methods Study

Stewardship Prompts to Improve Antibiotic Selection for Pneumonia

1029. Increased Mortality in Hospital-Onset Carbapenem-Resistant Enterobacterales Bloodstream Infections

Statistical analysis plan for the PRO B study: open-label, superiority randomised controlled trial of alarm-based patient-reported outcome monitoring in patients with metastatic breast cancer

Optimizing Research Data Acquisition with Smart Pill Bottles (SPBs), the ORDAS Trial: A Feasibility and Implementation Study Protocol